IBM Does an About-Face on Facial Recognition Technology: Business Casual

Powered by RedCircle

On this Business Casual snippet, Tyler Kern, Taylor Bagley and Daniel Litwin discuss an announcement made my IBM on June 8th regarding the tech giant’s intention to stop offering facial recognition software for “mass surveillance or racial profiling”.

In 2019, a study conducted by the Massachusetts Institute of Technology found that none of the facial recognition tools from Microsoft, Amazon and IBM were 100% accurate when it came to recognizing men and women with dark skin. Further, a study from the US National Institute of Standards and Technology suggested facial recognition algorithms were far less accurate at identifying African-American and Asian faces compared with Caucasian ones. In a world currently riding the shockwaves of social unrest and protests calling for police reform in the wake of George Floyd’s death while being apprehended by officers in Minneapolis, this technological bias in gear provided to policing organizations has definitely been put under the microscope.

In support of IBMs move to abandon ‘biased’ facial recognition tech, Chief Executive Arvind Krishna, stated, “We believe now is the time to begin a national dialogue on whether and how facial recognition technology should be employed by domestic law enforcement agencies”.

As the first major company to back out of a technology largely used by law enforcement, the Business Casual dynamic duo break down Krishna’s letter to congress urging action against police malfeasance as well as more regulation on how law enforcement uses facial recognition technology, two different studies of Amazon’s facial recognition system by the ACLU which resulted in both Congress members and professional athletes being falsely matched with images of those in a mugshot database, whether IBM’s decision was based solely on current racially-charged events or just part of an ongoing massive restructuring within the company, and much more.

Bringing thought leadership to your day, MarketScale’s Business Casual keeps you current with technology leaps both forward and backward, the hottest topics and the newest trends shaping business and our world today. And for the latest thought leadership, news and event coverage across B2B, be sure to check out our industry pages.

Follow us on social media for the latest updates in B2B!
Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More